We intend to carry on building our pipeline and develop our portfolio in the anti-infective field with the innovations that stem from our R&D teams.
We seek product licensing deals with pharmaceutical and biotechnology companies that would be interested in co-developing our products to tackle the gut microbiome dysbiosis consequences.
Da Volterra officially joined the COMBACTE-NET consortium in November 2016 and took the lead of Work Package 7.
Work Package 7 of COMBACTE-NET is entitled ANTICIPATE: AssessmeNT of the Incidence of Clostridium difficile Infections in hospitalized Patients on Antibiotic Treatment (ANTICIPATE). It is an observational, prospective, cohort study of patients receiving antibiotic treatment during hospitalization.
The aim of ANTICIPATE is to estimate the incidence of Clostridium difficile infection (CDI), antibiotic-associated diarrhea (AAD) and changes in the diversity and composition of the intestinal microbiota in patients aged 50 or older and receiving antibiotics during their hospitalization.
BIOASTER and Da Volterra signed an agreement to initiate a research partnership based on the novel economic model of Technology Research Institute (TRIs)
The project, entitled DACCAR, (Destroy Antibiotics in Colon to Combat Antibiotic Resistance), aims to develop an innovative product limiting the emergence of multi-resistant bacteria in patients treated with antibiotics to protect the intestinal microbial flora from antibiotics side effects.
Thus, using a DACCAR product would result in minimizing the nosocomial infections burden and maintaining effectiveness of antibiotics (noteworthy carbapenems) by reducing the spread of antibiotic resistance.
Da Volterra is a partner of the COMBACTE-CDI consortium which started in November 2017. The project aims to develop a detailed understanding of the epidemiology and clinical impact of Clostridium difficile infection across Europe.
A large epidemiology study will be undertaken across Europe to quantify the burden of CDI across the whole healthcare economy. In addition, a case/control study, which along with data collected in a questionnaire will enable the consortium to assess current practices in Europe and their potential impacts.
The ultimate goal is to contribute to improve treatment options for patients suffering from such infections that are responsible for extensive morbidity, mortality and health care costs.
TRAIN-ASAP (Training and Research Aimed at Novel Antibacterial Solutions in Animals and People) was a Marie Curie Initial Training Network funded under the 7th Framework Program of the European Commission.
TRAIN-ASAP addressed the lack of effective antibacterial drugs againt resistant bacteria which poses a serious threat to human health and has a huge economical consequences to the healthcare system.
The project was dedicated to the scientific and professional training of 14 early-stage researchers with the aim to develop novel antibacterial solutions for humans and animals. The consortium included 9 academic institutions, 8 private enterprises and 2 national research centers representing 10 countries.
EvoTAR (Evolution and Transfer of Antibiotic Resistance), was a project co funded by the European Commission.
Its objective was to study the evolution and spread of antibiotic resistance. EvoTAR aimed to characterize the resistome by investigating the interaction between resistant and non-resistant bacteria from the human microbiome and the interrelations of the human resistome with environmental, animal and food reservoirs of resistance genes.
EvoTAR was a 4-year project (2011-2015), during which Da Volterra had the unique opportunity to partner with scientific leaders investigating the complexity of the microbiota, developed in the MetaHIT European program, to study the evolution of the flora when submitted to antibiotic treatments with and without DAV132.
Led by Da Volterra, the NOSOBIO project was dedicated to the fight against nosocomial infections. It has received the support of Oséo (ISI program). It aimed to develop solutions for the prevention of bacterial resistance to antibiotics, and for diagnostic of patients colonized by multi-resistant bacteria at their entrance in the hospital and the identification of new antibiotics.
In Nosobio, Da Volterra was pooling its efforts with AP-HP, Institut Pasteur and Genewave to obtain the initial proof-of-concept of its products that have been recognized as breakthrough innovations in the management of resistant infections.